<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26872">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02080715</url>
  </required_header>
  <id_info>
    <org_study_id>COMT and vigilance</org_study_id>
    <nct_id>NCT02080715</nct_id>
  </id_info>
  <brief_title>Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Examination of the Effects of Tolcapone (TASMAR) on Vigilance in Healthy Volunteers After Sleep Deprivation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, pharmacologic effects of COMT inhibition during sleep deprivation in healthy
      subjects in dependence of their Val158Met genotype of COMT are studied. Potential effects
      are identified by measurement of vigilance and cognitive performance as well as EEG
      measurements during wake and sleep.

        -  Trial with medicinal product
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evolution of vigilance during prolonged wakefulness after intake of tolcapone when compared to placebo</measure>
    <time_frame>Participants will be studied during two weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vigilance is measured subjectively (questionnaires and visual analogue scales) and objectively (e.g., psychomotor vigilance task: reaction times and number of lapses; waking EEG: spectral power) at 3-hour intervals during 40 hours prolonged wakefulness in 30 healthy male adults.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tolcapone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tasmar</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone</intervention_name>
    <description>2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)</description>
    <arm_group_label>Tolcapone</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Tolcapone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy male subjects

          -  Age: 20-30 years

          -  written informed consent

          -  right handed

          -  non smoker

        Exclusion criteria:

          -  sleep disturbances

          -  irregular sleep-wake rhythm

          -  travelling with time-shift

          -  liver diseases (ALT: &gt; 82 U/l; AST: &gt; 76 U/l)

          -  diseases of the nervous system

          -  acute internal medicine diseases

          -  medication or drug abuse

          -  intake of more than 3 caffeine-containing drinks

          -  intake of more than 5 alcoholic drinks per week

          -  heart pacemaker or implanted medical devices

          -  Body-Mass-Index (BMI): 20&lt; BMI &gt;26
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Peter Landolt, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich, Institute of Pharmacology and Toxicology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Baumann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Department of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Sommerauer, MD</last_name>
    <phone>+41 (0)44 255 11 11</phone>
    <email>michael.sommerauer@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans-Peter Landolt, Professor</last_name>
    <email>landolt@pharma.uzh.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Zurich, Institute of Pharmacology and Toxicology</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep-wake</keyword>
  <keyword>regulation</keyword>
  <keyword>volunteers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
